Thrombophilic mutations and risk of retinal vein occlusion

Arquivos Brasileiros de Oftalmologia

Volumn 70, Issue 6, 2007, Pages 971-974

  Biancardi, Ana Luiza ^a,d   Gadelha, Telma ^a   Borges, Wander Inturias Sergillo ^b   de Moraes Jr , Haroldo Vieira ^a,c   Spector, Nelson ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Instituto Brasileiro de Oftalmologia (IBOL)   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Universidade Federal de São Paulo UNIFESP ^*  (Brazil)

Author keywords

Factor V; Methylenetetrahydrofolate reductase (NADPH2); Prothrombin; Retinal vein occlusion; Risk factors; Thrombophilia

Indexed keywords

EID: 39049148151     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492007000600016     Document Type: Article

References (40)

1. Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol. 1996;114(5):545-54.
2. Risk factors for branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Am J Ophthalmol. 1993; 116(3):286-96.
3. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64-7. Comment in: Nature. 1994;369(6475):14-5.
4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698-703.
5. Frosst P, Blom HJ, Milos R, Goyett P, Sheppard CA, Matthews RG, et al. A cadidate genetic risk factor for vascular disease: a common mutation in metylenetetrahydrofolate reductase. Nat Genet. 1995; 10(1): 111-3.
6. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparrently healthy men. N Engl J Med. 1995;332(14):912-7. Comment in: N Engl J Med. 1995;333(13):880-1. N Engl J Med. 1995;333(13):881.
7. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost. 1999;81(5):684-9.
8. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677→Val in-the methylene tetrahrydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost. 1997;77(5):818-21.
9. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperthomo-cysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998; 80(6):874-7.
10. Zheng YZ, Tong J, Do XP, Pu XQ, Zhou BT. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol 2000;109(4):870-4.
11. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SO, Blom NJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep venous thrombosis. Thromb Haemost. 1998;79(2):254-8.
12. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral Vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. Engl J Med. 1998;338(25):1793-7. Comment in: N Engl J Med. 1998;338(25):1840-1.
13. Gadelha T, André C, Jucá AA, Nucci M. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovacs Dis. 2005;19(1):49-52.
14. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, et al. Risk Factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41(3):603-8.
15. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114(10):1243-7.
16. Aras S, Yilmaz G, Alpas I, Baltaci V, Tayanq E, Aydin P. Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutation. Eur J Ophthalmol. 2001;11(4):351-5.
17. Kuhli C, Hattenbach LO, Scharrer I, Koch F, Ohrloff C. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefe's Arch Clin Exp Ophthalmol. 2002;240(3):163-8.
18. Johnson TM, El-Defrawy S, Hodge WG, Leonard BC, Kertes PJ, Taylor SAM, et al. Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion. Retina. 2001;21(2):161-6.
19. Weger M, Renner W, Steinbrugger I, Cichocki L, Temmel W, Stanger O, et al. Role of thrombophilic gene polymorphism in branch retinal vein occlusion. Ophthalmology. 2005;112(11):1910-5.
20. Scott JA, Arnold JJ, Currie JM, Broadfoot C, Davidson M, Kelly KF, et al. No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. Ophthalmologica. 2001;215(3):217-21.
21. Arsène S, Delahousse B, Regina S, Le Lez ML, Pisella PJ, Gruel Y. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost. 2005;94(1):101-6.
22. Backhouse O, Parapia L, Mahomed I, Lee D. Familial thrombophilia and retinal vein occlusion. Eye. 2000;14(Pt 1):13-7.
23. Incorvaia C, Prameggiani F, Costagliola C. Lamberti G, Ferraresi P, Bernardi F, et al. The heterozygous 20210A genotype prevalence in patients affected by central and branch retinal yein occlusion: a pilot study. Graefe's Arch Clin Exp Ophthalmol. 2001;239(4):251-6.
24. Boyd S, Owens D, Gin T, Bunco K, Sherafat H, Perry D, et al. Plasma homocysteine, methylene tetralhydrofolate reductase C677T and factor G20210A polymorphisms, factor VIII and VWF in central retinal vein occlusion. Br J Ophthalmol 2001;85(11):1313-S.
25. Loewenstein A, Goldstein M, Winder A, Lazar, M; Eldor A. Retinal Vein occlusion associated with methylenetetrahydrofiolate reductase mutation. Ophtalmology 2000;106(9):1817-20. Erratum in: Ophthalmology. 2000;107(2)228.
26. Marcucci R, Bertini L, Giusti B, Brunell T, Fedi S, Cellai AP, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001;86(3):722-6.
27. Di Crecchio L, Parodi MB, Sanguinetti G, Iacono P, Ravalico G. Hyperhomocysteinemia and the methylenetetrahydrofolate reductase 677-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology. 2004;(5):940-5.
28. Weger M, Stanger O, Deutschmann H, Temmel W, Renner W, Schmut O. et al. Hyperhomocyst(e)inemia, but not methylenetetrahydrofolate reductase C677T mutation, as risk factor in branch retinal vein occlusion. Ophthalmology. 2002;109(6):1105-9. Comment in: Opthalmology. 2003;110(10)2069; author reply 2069.
29. Larsson J, Olafsdottir E, Barrer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol. 1996;80(3):200-2.
30. Weger M, Stanger O, Deutschmann H, Temmel W, Ream W, Schmut O, et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in pair with central retinal vein occlusion. Graefe's Arch Clin Exp Ophthalmol. 2002;(240):286-90.
31. Hvarfner C, Hillarp A, Larsson J. Influence of factor V Leiden on the development of neovascularization secondary to central retinal venous occlusion. Br J Ophthalmol. 2003;87(3):305-6.
32. Warrant O, Moisseiev J, Rosenberg N, Vidne O, Yassur I, Zivelin A, et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis. 1998;9(7):617-22.
33. Cruciani F, Moramarco A, Curto T, Labate A, Recupero V, Conti L, et al. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. Clin Ter. 2003;154(5):299-303.
34. Cahill M, Karebatzaki M, Meleady R, Rofsum H, Ueland P, Shields D, et al. Raised plasma homocystem as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000;84(2):154-7.
35. Lahay JM, Tunc M, Kearney J, Modlinski B, Koo H, Johnson RN, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology. 2002;109 (1):126-31.
36. Terrazi P, Di Mico P, Quaglia I, Rossi LS, Bellartorre AG, Gaspari G, et al. Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion. Thromb J. 2005;3:13-8.
37. Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand. 2000;78(3)340-3.
38. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24(4):493-519.
39. Williamson TH. Central retinal vein occlusion: what's the story? Br J Ophthalmol. 1997;81(8):698-704.
40. Christoffersen NI, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999;106(11):2054-62.